Resilience in the Healthcare Sector
The healthcare sector has long been recognized as a resilient domain for investors. Companies in this field provide essential life-saving medicines, devices, and solutions that consumers rely on, regardless of economic conditions. The steady demand for healthcare products and services makes these businesses a valuable addition to a diversified investment portfolio, suitable for various market scenarios.
Promising Healthcare Stocks
If you're searching for healthcare stocks with appealing valuations, consider two noteworthy options: AbbVie and Pfizer.
1. AbbVie
AbbVie (NYSE: ABBV) has faced a slowdown in growth due to the loss of patent exclusivity for its leading drug, Humira. However, the company has strategically adapted to lessen the financial impact of this change. While AbbVie is expected to enter a transition phase in the coming quarters as Humira sales decline, it boasts a portfolio of several blockbuster drugs and a promising pipeline that long-term investors should carefully evaluate before making decisions.
AbbVie's lineup includes several high-performing medications, such as Venclexta, a crucial treatment for blood cancer, and immunology drugs like Skyrizi, which treats plaque psoriasis, psoriatic arthritis, and Crohn's disease, as well as Rinvoq, used for conditions like eczema and rheumatoid arthritis. In the last quarter alone, these three drugs achieved impressive year-over-year revenue growths of 11.5%, 44.8%, and 55.8%, respectively.
The company has also launched newer drugs, including Vraylar for schizophrenia and bipolar disorder, along with migraine treatments Ubrelvy and Qulipta, all of which have seen significant revenue increases. In the most recent quarter, AbbVie's total revenue rose over 4% year-over-year to $14.5 billion, with net earnings reaching $1.4 billion.
In addition to advancing its drug development efforts, AbbVie has made significant acquisitions, such as Celsius Therapeutics and Cerevel Therapeutics. The acquisition of Celsius has added multiple new candidates to its pipeline, potentially leading to a first-in-class investigational drug for inflammatory bowel disease. Meanwhile, acquiring Cerevel has strengthened AbbVie's neuroscience portfolio with Emraclidine, a promising next-generation antipsychotic currently undergoing clinical trials.
Another attractive aspect for investors considering AbbVie is its dividend, which has consistently increased over time. Over the past five years, AbbVie’s dividend has risen by 45%. The current yield is approximately 3%, about double the average yield of S&P 500 stocks. This strong history of dividend growth, combined with a stable business outlook, makes AbbVie a stock worthy of further consideration.
2. Pfizer
Pfizer (NYSE: PFE) offers another appealing investment opportunity, currently trading at a price-to-sales (P/S) ratio of 3. Following a remarkable surge during the pandemic, fueled by unprecedented sales of its COVID-19 vaccine and antiviral treatment, Pfizer's growth metrics are starting to stabilize.
This stabilization does not indicate stagnation for Pfizer. The company has effectively reinvested profits from its COVID-19-related sales into internal development projects and strategic acquisitions. Recently, Pfizer has completed several acquisitions, including Biohaven Pharmaceuticals, known for its migraine medication Nurtec, and Arena Pharmaceuticals, which specializes in immuno-inflammatory drugs, as well as oncology leader Seagen.
Among these acquisitions, the Seagen deal is projected to contribute around $10 billion in annual revenue by 2030, while also introducing a suite of blockbuster oncology drugs to Pfizer’s already extensive portfolio. This acquisition not only enhances Pfizer's pipeline but also adds already approved oncology treatments, bolstering its market presence in cancer care.
Despite a decline in COVID-19-related sales, Pfizer generated over $55 billion in revenue over the past year, supported by an operating cash flow of about $8 billion. Although the stock has experienced some recent declines, Pfizer remains committed to maintaining its dividend, which has soared to nearly a 6% yield, significantly higher than the S&P 500's average of 1.5%. Notably, Pfizer’s dividend payout has increased by approximately 17% over the last five years.
With a robust 175-year history, Pfizer has successfully navigated various business cycles. There’s little reason to believe that this transitional period, following its pandemic highs, will deviate from that historical trend. Investors may find it advantageous to consider investing while the stock is priced below traditional valuations.
Investment Considerations
Before investing in AbbVie or Pfizer, it's crucial to assess your financial goals, risk tolerance, and how these stocks might fit into your overall investment strategy. Both companies offer unique strengths and potential growth paths that could align well with an investor’s long-term objectives.
Frequently Asked Questions
What makes AbbVie a good investment opportunity?
AbbVie has a diverse portfolio of blockbuster drugs, a strong history of dividend growth, and promising future potential due to ongoing product developments and acquisitions.
How has Pfizer adjusted post-pandemic?
Pfizer has refocused on internal development and strategic acquisitions as revenue normalizes after the pandemic, aiming to sustain its growth momentum.
What is the current dividend yield for AbbVie?
AbbVie currently offers a dividend yield of about 3%, which is quite attractive compared to the average yields of stocks in the market.
Why is the healthcare sector considered resilient for investments?
The healthcare sector typically shows strong demand even during economic downturns, making it a safer investment option for many investors.
What should investors consider before investing in these stocks?
Investors should evaluate their financial goals, risk appetite, and how either company fits within their overall investment strategies before making any purchases.
